David A. Siegel Pacira Bio Sciences, Inc. Transaction History
Two Sigma Advisers, LP
- $42.5 Billion
- Q1 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 91,200 shares of PCRX stock, worth $2.61 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
91,200
Previous 81,700
11.63%
Holding current value
$2.61 Million
Previous $2.76 Million
3.34%
% of portfolio
0.01%
Previous 0.01%
Shares
24 transactions
Others Institutions Holding PCRX
# of Institutions
286Shares Held
48.7MCall Options Held
156KPut Options Held
623K-
Black Rock Inc. New York, NY7.91MShares$226 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.11MShares$146 Million0.0% of portfolio
-
Frontier Capital Management CO LLC1.91MShares$54.8 Million0.55% of portfolio
-
State Street Corp Boston, MA1.9MShares$54.5 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.88MShares$53.8 Million0.09% of portfolio
About Pacira BioSciences, Inc.
- Ticker PCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 45,824,200
- Market Cap $1.31B
- Description
- Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...